Skip to content
OpenCapital
Get started

Catalyst Pharmaceutical CPRX Cash & Equivalents

Cash & Equivalents at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
$833.99M-43.7%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$33.21M-33.5%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$282.21M+29.6%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$753.1M+59.5%
Scholar Rock logo
Scholar RockSRRK
$430.54M+212%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$197.66M+234%

Other financials

Income statement

See full
Revenue$149.4M+5.6%
Gross profit$134.9M+9.2%
Operating income$73.2M+15.6%
Net income$63.7M+12.3%
EPS (diluted)$0.50+11.1%

Balance sheet

See full
Total debt$2.7M-13.3%
Total equity$1.0B+27.5%
Total assets$1.1B+26.3%

Cash flow

See full
Operating cash flow$59.6M-0.8%
CapEx$27.0K—
Free cash flow$59.6M-0.8%

Valuation

See full
Market cap$3.84B+2.7%
Enterprise value$3.09B-4.1%
P/E17.4×-1.6×
P/S6.4×-0.6×

Profitability

See full
Gross margin86%-0.2pp
Operating margin44.8%+1.6pp
Net margin37.1%+0.2pp
FCF margin34.9%-15.2pp

Returns & leverage

See full
Return on equity24.5%-4.6pp
Debt / equity0×0.0×
Current ratio7.1×+1.0×

Where this comes from

Reported directly by Catalyst Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Catalyst Pharmaceutical's cash & equivalents?
Catalyst Pharmaceutical (CPRX) reported cash & equivalents of $755.86M in Q1 2026.
How has Catalyst Pharmaceutical's cash & equivalents changed year-over-year?
Catalyst Pharmaceutical's cash & equivalents increased by 30.2% year-over-year, from $580.66M to $755.86M.
What is the long-term trend for Catalyst Pharmaceutical's cash & equivalents?
Over 5 years (2020 to 2025), Catalyst Pharmaceutical's cash & equivalents has grown at a 40.3% compound annual growth rate (CAGR), from $130.24M to $709.17M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.